What's Happening?
Latus Bio will present new data on its investigational gene therapies for Huntington's disease and CLN2 disease at the ASGCT meeting. The presentations will include computational and preclinical data supporting the advancement of LTS-201 and LTS-101 programs.
Founder Beverly Davidson, Ph.D., will receive the ASGCT Outstanding Achievement Award for her contributions to gene-based therapeutic strategies.
Why It's Important?
The data presented by Latus Bio highlights the potential of gene therapy to address complex neurological disorders like Huntington's and CLN2 diseases. These therapies could offer new hope for patients with limited treatment options, potentially altering disease progression. The recognition of Beverly Davidson's work underscores the importance of pioneering research in advancing therapeutic innovations.
